MANKIND · Health Care · 2026-08-07

Mankind Pharma Ltd

4.4WatchEven +1.3Stage 2 · wk 9In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹2,456
+1.48% today
₹1,01,432 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Visit company website →
P/E (TTM)
52.3
Forward 33.7
Earnings Growth (YoY)
+31.7%
Revenue +11.8%
ROE
+12.5%
Profit margin +13.4%
Dividend Yield
0.08%
P/B 6.5
vs 52W High
-7.7%
₹1,927.4 lo₹2,660.6 hi
7.7% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 9
1w13w26w
Week 9 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
7.8%
200 DMA: ₹2,277.8 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.34x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
→
MA20 flat · -0.2% vs MA50 +1.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #64 of 79 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #41 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S? 41w
S2 15w
S2 23w
S4 23w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S2 15w → S3 10w → S2 23w → S3 6w → S4 8w → S1 7w → S4 4w → S1 5w → S2 5w → S3 6w → S4 23w → S1 6w → S2 8w current
Total tracked: 168 weeks across 14 stage runs.
1M
-3.0%
3M
+1.0%
6M
+19.0%
YTD
+12.6%
1Y
-4.6%
Scan Membership
Breakout Watch
Latest: 2026-06-11
4 appearances in last 60 days. First seen: 2024-02-26.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 9 · Vol —x
2026-08-06S2
Wk 8 · Vol —x
2026-08-05S2
Wk 8 · Vol —x
2026-08-04S2
Wk 8 · Vol —x
2026-08-03S2
Wk 8 · Vol —x
2026-07-31S2
Wk 8 · Vol —x
2026-07-30S2
Wk 7 · Vol —x
2026-07-29S2
Wk 7 · Vol —x
2026-07-28S2
Wk 7 · Vol —x
2026-07-27S2
Wk 7 · Vol —x
2026-07-24S2
Wk 7 · Vol —x
2026-07-23S2
Wk 6 · Vol —x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹2,468.5
200 DMA
₹2,277.8
52W High
₹2,660.6
52W Low
₹1,927.4
5D Low
₹2,420.3
Resistance levels (recent highs)
20d High
₹2,617.9
60d High
₹2,617.9
120d High
₹2,617.9
250d High
₹2,660.6
Next resistance
+6.6%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.